Investigating glycogenosis type III patients with multi-parametric functional NMR imaging and spectroscopy

Neuromuscular Disorders

Volumn 20, Issue 8, 2010, Pages 548-558

  Wary, Claire ^a,b,c   Nadaj Pakleza, Aleksandra ^d,e   Laforêt, Pascal ^a,d   Claeys, Kristl G ^a,d   Carlier, Robert ^a,f   Monnet, Aurélien ^a,b,c   Fleury, Servanne ^a,b,c   Baligand, Céline ^a,b,c   Eymard, Bruno ^a,d   Labrune, Philippe ^g   Carlier, Pierre G ^a,b,c  

^a Institute of Myology   (France)

^b DIF   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f RAYMOND POINCARÉ HOSPITAL   (France)

^g HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

BOLD; Debranching enzyme; Glycogen; Glycogen storage disease; Imaging; Muscle function; Myopathy; NMR; Perfusion; Spectroscopy

Indexed keywords

CREATINE PHOSPHATE; MYOGLOBIN;

ADOLESCENT; ADULT; AEROBIC EXERCISE; AGED; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EXERCISE TOLERANCE; FEMALE; GASTROCNEMIUS MUSCLE; GLYCOGEN MUSCLE LEVEL; GLYCOGEN STORAGE DISEASE TYPE 3; HUMAN; HUMAN TISSUE; MALE; MUSCLE BIOPSY; MUSCLE PERFUSION; MUSCLE WEAKNESS; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PH; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; CHILD; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENERGY METABOLISM; EXERCISE; FEMALE; GLYCOGEN; GLYCOGEN STORAGE DISEASE TYPE III; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; MYOGLOBIN; OXYGEN CONSUMPTION; PHOSPHORUS; REGIONAL BLOOD FLOW; YOUNG ADULT;

EID: 77955277898     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2010.06.011     Document Type: Article

References (60)

1. Forbes G.B. Glycogen storage disease; report of a case with abnormal glycogen structure in liver and skeletal muscle. J Pediatr 1953, 42:645-653.
2. Illingworth B., Cori G.T., Cori C.F. Amylo-1,6-glucosidase in muscle tissue in generalized glycogen storage disease. J Biol Chem 1956, 218:123-129.
3. Coleman R.A., Winter H.S., Wolf B., Gilchrist J.M., Chen Y.T. Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy. Ann Intern Med 1992, 116:896-900.
4. Kiechl S., Willeit J., Vogel W., Kohlendorfer U., Poewe W. Reversible severe myopathy of respiratory muscles due to adult-onset type III glycogenosis. Neuromuscul Disord 1999, 9:408-410.
5. Momoi T., Sano H., Yamanaka C., Sasaki H., Mikawa H. Glycogen storage disease type III with muscle involvement: reappraisal of phenotypic variability and prognosis. Am J Med Genet 1992, 42:696-699.
6. Shen J., Bao Y., Liu H.M., Lee P., Leonard J.V., Chen Y.T. Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J Clin Invest 1996, 98:352-357.
7. Lucchiari S., Pagliarani S., Salani S., Filocamo M., Di Rocco M., Melis D., et al. Hepatic and neuromuscular forms of glycogenosis type III: nine mutations in AGL. Hum Mutat 2006, 27:600-601.
8. Shaiu W.L., Kishnani P.S., Shen J., Liu H.M., Chen Y.T. Genotype-phenotype correlation in two frequent mutations and mutation update in type III glycogen storage disease. Mol Genet Metab 2000, 69:16-23.
9. Walton J., Rowland L. Clinical examination, differential diagnosis and classification. Disorders of Voluntary Muscle 1994, 1771. Churchill Livingstone, New York. sixth ed. J. Walton, G. Karpati, D. Hilton-Jones (Eds.).
10. Raynaud J.S., Carlier P.G., Wary C., Duteil S., Leroy-Willig A., Vaughan J.T., et al. Improved methodology for dynamic studies of muscle oxygen metabolism using 1H/31P imaging/spectroscopy protocols (Abstract). MAGMA 1999, 9:150.
11. 13C NMR spectroscopy. MAGMA 2000, 11:153.
12. 13C NMR spectroscopy. Neuromuscul Disord 1991, 1:99-101.
13. 13C NMR spectroscopy in adult-onset acid maltase deficiency. Neuromuscul Disord 2003, 13:545-553.
14. Mercuri E., Pichiecchio A., Allsop J., Messina S., Pane M., Muntoni F. Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging 2007, 25:433-440.
15. 31P nuclear magnetic resonance study. Mol Biol Med 1983, 1:77-94.
16. 31P NMR spectroscopy of calf muscles coupled with MRI and ergometry. Rev Neurol (Paris) 2003, 159:56-67.
17. 31P MRS. The role of pH in the evaluation of phosphocreatine and inorganic phosphate recoveries from exercise. NMR Biomed 1993, 6:248-253.
18. Raynaud J.S., Duteil S., Vaughan J.T., Hennel F., Wary C., Leroy-Willig A., et al. Determination of skeletal muscle perfusion using arterial spin labeling NMRI: validation by comparison with venous occlusion plethysmography. Magn Reson Med 2001, 46:305-311.
19. Brillault-Salvat C., Giacomini E., Wary C., Peynsaert J., Jouvensal L., Bloch G., et al. An interleaved heteronuclear NMRI-NMRS approach to non-invasive investigation of exercising human skeletal muscle. Cell Mol Biol (Noisy-le-grand) 1997, 43:751-762.
20. Carlier P.G., Brillault-Salvat C., Giacomini E., Wary C., Bloch G. How to investigate oxygen supply, uptake, and utilization simultaneously by interleaved NMR imaging and spectroscopy of the skeletal muscle. Magn Reson Med 2005, 54:1010-1013.
21. Toussaint J.F., Kwong K.K., Mkparu F.O., Weisskoff R.M., LaRaia P.J., Kantor H.L. Perfusion changes in human skeletal muscle during reactive hyperemia measured by echo-planar imaging. Magn Reson Med 1996, 35:62-69.
22. Lebon V., Brillault-Salvat C., Bloch G., Leroy-Willig A., Carlier P.G. Evidence of muscle BOLD effect revealed by simultaneous interleaved gradient-echo NMRI and myoglobin NMRS during leg ischemia. Magn Reson Med 1998, 40:551-558.
23. Duteil S., Wary C., Raynaud J.S., Lebon V., Lesage D., Leroy-Willig A., et al. Influence of vascular filling and perfusion on BOLD contrast during reactive hyperemia in human skeletal muscle. Magn Reson Med 2006, 55:450-454.
24. Damon B.M., Wadington M.C., Hornberger J.L., Lansdown D.A. Absolute and relative contributions of BOLD effects to the muscle functional MRI signal intensity time course: effect of exercise intensity. Magn Reson Med 2007, 58:335-345.
25. Meyer R.A., Prior B.M. Functional magnetic resonance imaging of muscle. Exerc Sport Sci Rev 2000, 28:89-92.
26. Richardson R.S., Newcomer S.C., Noyszewski E.A. Skeletal muscle intracellular PO(2) assessed by myoglobin desaturation: response to graded exercise. J Appl Physiol 2001, 91:2679-2685.
27. Duteil S., Bourrilhon C., Raynaud J.S., Wary C., Richardson R.S., Leroy-Willig A., et al. Metabolic and vascular support for the role of myoglobin in humans: a multiparametric NMR study. Am J Physiol Regul Integr Comp Physiol 2004, 287:R1441-1449.
28. Dubowitz V., Sewry C.A. Muscle Biopsy: A Practical Approach 2007, Saunders Elsevier, London. 3rd ed.
29. Monnet A., Wary C., Wuyam B., Verges S., Duteil S., Carlier P.G. Influence of workload on human calf muscle following dynamic aerobic exercise: BOLD effect, perfusion, oxygenation and energetics assessed by mpf-NMR. MAGMA 2008, 21(Suppl. 1):92.
30. Edwards R.H., Dawson M.J., Wilkie D.R., Gordon R.E., Shaw D. Clinical use of nuclear magnetic resonance in the investigation of myopathy. Lancet 1982, 1:725-731.
31. Chan W.P., Liu G.C. MR imaging of primary skeletal muscle diseases in children. AJR Am J Roentgenol 2002, 179:989-997.
32. Kuo G.P., Carrino J.A. Skeletal muscle imaging and inflammatory myopathies. Curr Opin Rheumatol 2007, 19:530-535.
33. Lovitt S., Moore S.L., Marden F.A. The use of MRI in the evaluation of myopathy. Clin Neurophysiol 2006, 117:486-495.
34. Ozsarlak O., Schepens E., Parizel P.M., Van Goethem J.W., Vanhoenacker F., De Schepper A.M., et al. Hereditary neuromuscular diseases. Eur J Radiol 2001, 40:184-197.
35. de Kerviler E., Leroy-Willig A.L.W., Duboc D., Eymard B., Syrota A. MR quantification of muscle fatty replacement in McArdle's disease. Magn Reson Imaging 1996, 14:1137-1141.
36. Pichiecchio A., Uggetti C., Ravaglia S., Egitto M.G., Rossi M., Sandrini G., et al. Muscle MRI in adult-onset acid maltase deficiency. Neuromuscul Disord 2004, 14:51-55.
37. Brooke M.H., Fenichel G.M., Griggs R.C., Mendell J.R., Moxley R., Miller J.P., et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the " power" of therapeutic trials based on the natural history. Muscle Nerve 1983, 6:91-103.
38. Lord J.P., Lieberman J.S., Portwood M.M., Fowler W.M., Carson R. Functional ability and equipment use among patients with neuromuscular disease. Arch Phys Med Rehabil 1987, 68:348-352.
39. Seelig J., Burlina A.P. Carbon-13 magnetic resonance in biology and medicine. Clin Chim Acta 1992, 206:125-136.
40. Jehenson P., Duboc D., Labrune P., Fardeau M., Odievre M., Syrota A. Diagnostic value of the evaluation of the glycogen content in muscle diseases by carbon 13 nuclear magnetic resonance. J Chim Phys 1995, 92:1797-1800.
41. 13C NMR spectroscopy of lipids: a simple method for absolute quantitation. Anticancer Res 1996, 16:1479-1484.
42. Tarnopolsky M.A., Parise G. Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle Nerve 1999, 22:1228-1233.
43. Cornelio F., Bresolin N., Singer P.A., DiMauro S., Rowland L.P. Clinical varieties of neuromuscular disease in debrancher deficiency. Arch Neurol 1984, 41:1027-1032.
44. Kiechl S., Kohlendorfer U., Thaler C., Skladal D., Jaksch M., Obermaier-Kusser B., et al. Different clinical aspects of debrancher deficiency myopathy. J Neurol Neurosurg Psychiatry 1999, 67:364-368.
45. Griffin J.L. Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows Arch B Cell Pathol Incl Mol Pathol 1984, 45:23-36.
46. Raben N., Danon M., Gilbert A.L., Dwivedi S., Collins B., Thurberg B.L., et al. Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 2003, 80:159-169.
47. 31P NMR spectroscopy of myopathies: clinical application of whole-body MR. Radiat Med 1986, 4:41-45.
48. Duboc D., Jehenson P., Tran Dinh S., Marsac C., Syrota A., Fardeau M. Phosphorus NMR spectroscopy study of muscular enzyme deficiencies involving glycogenolysis and glycolysis. Neurology 1987, 37:663-671.
49. 1H NMR investigation in vitro of normal and abnormal human liver. Biochim Biophys Acta 1993, 1225:71-77.
50. 31P NMR studies of control of mitochondrial function in phosphofructokinase-deficient human skeletal muscle. Proc Natl Acad Sci USA 1982, 79:7714-7718.
51. Roach P.J. Glycogen and its metabolism. Curr Mol Med 2002, 2:101-120.
52. Lomako J., Lomako W.M., Kirkman B.R., Whelan W.J. The role of phosphate in muscle glycogen. Biofactors 1994, 4:167-171.
53. Tagliabracci V.S., Turnbull J., Wang W., Girard J.M., Zhao X., Skurat A.V., et al. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc Natl Acad Sci USA 2007, 104:19262-19266.
54. Argov Z., Lofberg M., Arnold D.L. Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy. Muscle Nerve 2000, 23:1316-1334.
55. De Stefano N., Argov Z., Matthews P.M., Karpati G., Arnold D.L. Impairment of muscle mitochondrial oxidative metabolism in McArdles's disease. Muscle Nerve 1996, 19:764-769.
56. Lewis S.F., Haller R.G., Cook J.D., Nunnally R.L. Muscle fatigue in McArdle's disease studied by 31P-NMR: effect of glucose infusion. J Appl Physiol 1985, 59:1991-1994.
57. Carlier P.G., Bertoldi D., Baligand C., Wary C., Fromes Y. Muscle blood flow and oxygenation measured by NMR imaging and spectroscopy. NMR Biomed 2006, 19:954-967.
58. Ismail H. Glycogen storage disease type III presenting with secondary diabetes and managed with insulin: a case report. Cases J 2009, 2:6891.
59. Spengos K., Michelakakis H., Vontzalidis A., Zouvelou V., Manta P. Diabetes mellitus associated with glycogen storage disease type III. Muscle Nerve 2009, 39:876-877.
60. Oki Y., Okubo M., Tanaka S., Nakanishi K., Kobayashi T., Murase T. Diabetes mellitus secondary to glycogen storage disease type III. Diabet Med 2000, 17:810-812.